E Fund Management Co. Ltd. Boosts Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

E Fund Management Co. Ltd. boosted its stake in Denali Therapeutics Inc. (NASDAQ:DNLI) by 32.2% during the 4th quarter, Holdings Channel reports. The firm owned 9,997 shares of the company’s stock after buying an additional 2,436 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Denali Therapeutics were worth $204,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Principal Financial Group Inc. increased its holdings in shares of Denali Therapeutics by 13.8% in the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after purchasing an additional 149,939 shares during the last quarter. Assetmark Inc. boosted its stake in Denali Therapeutics by 18.0% during the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after buying an additional 580 shares during the period. Victory Capital Management Inc. increased its position in Denali Therapeutics by 163.7% during the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock valued at $1,162,000 after acquiring an additional 24,767 shares during the last quarter. Thrivent Financial for Lutherans increased its position in Denali Therapeutics by 6.4% during the third quarter. Thrivent Financial for Lutherans now owns 138,862 shares of the company’s stock valued at $4,045,000 after acquiring an additional 8,358 shares during the last quarter. Finally, Swiss National Bank raised its stake in shares of Denali Therapeutics by 7.7% in the third quarter. Swiss National Bank now owns 250,700 shares of the company’s stock valued at $7,303,000 after acquiring an additional 17,900 shares during the period. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on DNLI. Robert W. Baird started coverage on shares of Denali Therapeutics in a research note on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price target for the company. Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They set a “buy” rating and a $31.00 target price on the stock. JPMorgan Chase & Co. decreased their price target on Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday, January 7th. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective for the company in a report on Monday, December 16th. Finally, William Blair reiterated an “outperform” rating on shares of Denali Therapeutics in a research note on Friday, February 28th. Two research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $37.27.

Insider Activity

In other Denali Therapeutics news, Director Steve E. Krognes sold 3,339 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the completion of the sale, the director now directly owns 25,757 shares of the company’s stock, valued at approximately $536,003.17. This represents a 11.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Vicki L. Sato sold 3,080 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now owns 107,976 shares in the company, valued at $2,257,778.16. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 47,940 shares of company stock worth $973,442. 7.90% of the stock is currently owned by company insiders.

Denali Therapeutics Stock Performance

NASDAQ DNLI opened at $16.69 on Monday. Denali Therapeutics Inc. has a one year low of $14.01 and a one year high of $33.33. The company has a market capitalization of $2.42 billion, a price-to-earnings ratio of -6.05 and a beta of 1.46. The company’s 50-day simple moving average is $20.80 and its two-hundred day simple moving average is $24.30.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.08. Equities analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.